The effects and efficacy of trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a targeted immunotherapy used to treat HER2 (human epidermal growth factor receptor 2)-positive breast cancer. HER2-positive breast cancer cells overexpress - have an excess amount - of the HER2 receptor protein on their surface. HER2 (formerly HER2/Neu) helps cancer cells grow and divide quickly. Trastuzumab injection (subcutaneous ) is administered via rapid subcutaneous injection within 2-5 minutes, which is the same as trastuzumab for injection (

Trastuzumab injection (subcutaneous ) contains a monoclonal antibody called trastuzumab. Trastuzumab is a HER2 inhibitor that blocks the growth and division of cancer cells by targeting and binding to HER2. Trastuzumab initiates antibody-dependent cell-mediated cytotoxicity (ADCC), which means it allows your own immune system cells to target and kill cancer cells coated with antibodies. Rapid dosing of trastuzumab injection (subcutaneous injection) is made possible by the addition of hyaluronidase, an enzyme that temporarily acts at the injection site to help absorb trastuzumab into the bloodstream.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.